The patient’s identity and gender are confidential, but his or her blood is at the center of an experiment that could transform medicine. He or she suffers from aplastic anemia, a condition that prevents the patient from producing enough blood cells, including platelets, the tiny cells that help blood clot. The patient also experiences platelet transfusion refractoriness, meaning the body rejects blood from most donors. At a lab in Kyoto, Japan, scientists are running a pioneering clinical trial to treat this singular patient...

Source: Wall Street Journal September 04, 2020 13:07 UTC